[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657952":3},{"organization":4,"outcomesModule":7,"designInfo":97,"detailedDescription":11,"studyPopulation":11,"armGroups":108,"interventions":119,"overallOfficials":11,"centralContacts":130,"locations":138,"responsibleParty":173,"collaborators":175,"id":178,"slug":179,"hasResults":180,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":180,"sex":186,"minAge":187,"maxAge":11,"enrollmentInfo":188,"targetDuration":11,"studyType":191,"phases":192,"briefSummary":194,"conditions":195,"keywords":11,"overallStatus":141,"whyStopped":11,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":206},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage Change in Body Weight from Baseline",null,"From Baseline to Week 64",[14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,57,59,61,63,65,67,69,71,73,75,77,79,81,83,85,87,89,91,93,95],{"measure":15,"description":11,"timeFrame":12},"Proportion of Participants Achieving ≥ 5% Body Weight Loss from Baseline",{"measure":17,"description":11,"timeFrame":12},"Proportion of Participants Achieving ≥ 10% Body Weight Loss from Baseline",{"measure":19,"description":11,"timeFrame":12},"Proportion of Participants Achieving ≥ 15% Body Weight Loss from Baseline",{"measure":21,"description":11,"timeFrame":12},"Change from Baseline in Waist Circumference (cm)",{"measure":23,"description":11,"timeFrame":12},"Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)",{"measure":25,"description":11,"timeFrame":12},"Change from Baseline in Triglycerides",{"measure":27,"description":11,"timeFrame":12},"Change from Baseline in High-Density Lipoprotein (HDL) Cholesterol",{"measure":29,"description":11,"timeFrame":12},"Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQoL-Lite-CT) Physical Functioning Composite Score",{"measure":31,"description":11,"timeFrame":12},"Change from Baseline in IWQoL-Lite-CT Physical Functioning Composite Score in Participants with Poor Physical Functioning at Baseline (as defined by Patient Global Impression of Severity\u002FStatus [PGI-S])",{"measure":33,"description":11,"timeFrame":12},"Change from Baseline in Short Form (36) Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score",{"measure":35,"description":11,"timeFrame":12},"Change from Baseline in SF-36v2 Acute Form Physical Functioning Domain Score in Participants with Poor Physical Functioning at Baseline (as defined by PGI-S)",{"measure":37,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Food Craving Score",{"measure":39,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Peak Hunger Score",{"measure":41,"description":11,"timeFrame":12},"Change from Baseline in Body Mass Index (BMI) (kg\u002Fm²)",{"measure":43,"description":11,"timeFrame":12},"Change from Baseline in Body Weight (kg)",{"measure":45,"description":11,"timeFrame":12},"Change from Baseline in Waist-to-Hip Ratio",{"measure":47,"description":11,"timeFrame":12},"Change from Baseline in Waist-to-Height Ratio",{"measure":49,"description":11,"timeFrame":12},"Change from Baseline in Fasting Insulin",{"measure":51,"description":11,"timeFrame":12},"Change from Baseline in Fasting Glucose",{"measure":53,"description":11,"timeFrame":12},"Change from Baseline in Hemoglobin A1c (HbA1c)",{"measure":55,"description":11,"timeFrame":56},"Percentage of Participants Achieving HbA1c of \u003C5.7%","At Week 64",{"measure":58,"description":11,"timeFrame":12},"Change from Baseline in Very-Low-Density Lipoprotein (VLDL) Cholesterol",{"measure":60,"description":11,"timeFrame":12},"Change from Baseline in Non-HDL Cholesterol",{"measure":62,"description":11,"timeFrame":12},"Change from Baseline in Total Cholesterol",{"measure":64,"description":11,"timeFrame":12},"Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol",{"measure":66,"description":11,"timeFrame":12},"Change from Baseline in Free Fatty Acids",{"measure":68,"description":11,"timeFrame":12},"Change from Baseline in Systolic Blood Pressure",{"measure":70,"description":11,"timeFrame":12},"Change from Baseline in Diastolic Blood Pressure",{"measure":72,"description":11,"timeFrame":12},"Change from Baseline in Health-Related Quality of Life (HRQoL) as assessed by SF-36v2 Acute Form Domain Scores and Component Summary Scores",{"measure":74,"description":11,"timeFrame":12},"Change from Baseline in HRQoL as assessed by IWQoL-Lite-CT Domain Scores and Total Score",{"measure":76,"description":11,"timeFrame":12},"Proportion of Participants with ≥ 14.6-Point Increase from Baseline in IWQoL-Lite-CT Physical Function Score",{"measure":78,"description":11,"timeFrame":12},"Proportion of Participants with ≥ 3.7-Point Increase from Baseline in SF36v2 Physical Functioning Score",{"measure":80,"description":11,"timeFrame":12},"Proportion of Participants with Baseline Poor Physical Functioning Achieving ≥ 14.6-Point Increase in IWQoL-Lite-CT Physical Functioning Score",{"measure":82,"description":11,"timeFrame":12},"Proportion of Participants with Baseline Poor Physical Functioning Achieving a ≥ 3.7-Point Increase in SF36v2 Physical Functioning Score",{"measure":84,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Average Hunger Score",{"measure":86,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Average Satiety Score",{"measure":88,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Average Appetite Score",{"measure":90,"description":11,"timeFrame":12},"Incidence and Severity of Adverse Events, with Severity Determined According to Mild\u002FModerate\u002FSevere Criteria",{"measure":92,"description":11,"timeFrame":12},"Percentage of Participants with Baseline Anti-Drug Antibodies (ADAs) and Treatment-Emergent ADAs Against Petrelintide",{"measure":94,"description":11,"timeFrame":12},"Change from Baseline in Total Fat Mass",{"measure":96,"description":11,"timeFrame":12},"Change from Baseline in Total Lean Mass",{"allocation":98,"interventionModel":99,"interventionModelDescription":11,"primaryPurpose":100,"observationalModel":11,"timePerspective":11,"maskingInfo":101},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":102,"maskingDescription":11,"whoMasked":103},"QUADRUPLE",[104,105,106,107],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[109,114],{"label":110,"type":111,"description":11,"interventionNames":112},"Petrelintide","EXPERIMENTAL",[113],"Combination Product: Petrelintide",{"label":115,"type":116,"description":11,"interventionNames":117},"Placebo","PLACEBO_COMPARATOR",[118],"Combination Product: Placebo",[120,127],{"type":121,"name":110,"description":122,"armGroupLabels":123,"otherNames":124},"COMBINATION_PRODUCT","Petrelintide will be administered subcutaneously (SC) using a drug-device combination product.",[110],[125,126],"RO7895515","ZP8396",{"type":121,"name":115,"description":128,"armGroupLabels":129,"otherNames":11},"Petrelintide-matching placebo will be administered SC using a drug-device combination product.",[115],[131,136],{"name":132,"role":133,"phone":134,"phoneExt":11,"email":135},"Reference Study ID Number: CC46368 https:\u002F\u002Fforpatients.roche.com\u002FNo attachments to email below.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":137,"role":133,"phone":11,"phoneExt":11,"email":11},"Fastest Response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[139,153,163],{"facility":140,"status":141,"city":142,"state":143,"zip":144,"country":145,"countryCode":146,"cosmosGeoPoint":147,"geoPoint":152,"contacts":11},"Pinnacle Research Group","RECRUITING","Anniston","Alabama","36207","United States","US",{"type":148,"coordinates":149},"Point",[150,151],-85.83163,33.65983,{"lat":151,"lon":150},{"facility":154,"status":141,"city":155,"state":156,"zip":157,"country":145,"countryCode":146,"cosmosGeoPoint":158,"geoPoint":162,"contacts":11},"Progressive Medical Research","Port Orange","Florida","32127",{"type":148,"coordinates":159},[160,161],-80.99561,29.13832,{"lat":161,"lon":160},{"facility":164,"status":141,"city":165,"state":166,"zip":167,"country":145,"countryCode":146,"cosmosGeoPoint":168,"geoPoint":172,"contacts":11},"Clinical Research Associates","Nashville","Tennessee","37203",{"type":148,"coordinates":169},[170,171],-86.78444,36.16589,{"lat":171,"lon":170},{"type":174,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[176],{"name":177,"class":6},"Zealand Pharma","100657952","phase-3-a-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-petrelintide-in-participants-with-overweight-or-obesity-100657952",false,"NCT07843498","A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity","ZUPREME-3","Inclusion Criteria:\n\n* Participants with BMI ≥ 30 kg\u002Fm² or BMI ≥ 27 kg\u002Fm² with at least one weight-related comorbidity\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n\nExclusion Criteria:\n\n* HbA1c ≥ 48 mmol\u002Fmol (6.5%), measured by the central laboratory at screening\n* Known history of Type 1 or Type 2 diabetes mellitus\n* Current or previous treatment with petrelintide or any other amylin analog","ALL","18 Years",{"count":189,"type":190},3900,"ESTIMATED","INTERVENTIONAL",[193],"PHASE3","This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, and without Type 2 Diabetes (T2D).",[196],"Obesity or Overweight","2026-10-05",{"date":199,"type":200},"2026-10-07","ACTUAL",{"date":202,"type":200},"2026-09-30",{"date":204,"type":190},"2029-03-22",{"name":5,"class":6},3]